Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2016

S1

Supporting Information

I_2 mediated synthesis of 5-substituted-3-methyl/benzyl-1,3,4-oxadiazol-2(*3H*)-ones via sequential condensation/oxidative cyclization and rearrangement

Shyam Sunder Patel,^a Nisha Chandna,^a Shreemoyee Kumar,^a and Nidhi Jain*^a

Department of Chemistry, Indian Institute of Technology, New Delhi-110016

*E-mail: njain@chemistry.iitd.ac.in

List of Contents:

1.	Crystallographic description	S1-S3
2.	Spectra of synthesized compounds	S4-S33

Crystallographic Description:

Data Collection and Refinement Single-crystal X-ray data of compounds was collected on Bruker SMART CCD Diffractometer using graphite monochromated MoK α radiation ($\lambda = 0.71073$ Å). Frames were collected at T = 298 K by ω , φ , and 2 θ -rotations with full quadrant data collection strategy (four domains each with 600 frames) at 10s per frame with SMART. The measured intensities were reduced to F² and corrected for absorption with SADABS.¹ Structure solution, refinement, and data output were carried out with the SHELXTL package by direct methods.² Non-hydrogen atoms were refined anisotropically using the WinGX (version 1.80.05) program package.³ All non-hydrogen atoms were refined anisotropically and hydrogen atoms were treated as riding atoms using SHELX default parameters. Molecular structures were drawn using ORTEP software shown in figure S1. Further information on the crystal structure determination (excluding structure factors) has been given as table S1 and also deposited in the Cambridge Crystallographic Data Centre as supplementary publications no. 1420804. Copies of the data can be obtained free of charge upon application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: (+44) 1223-336-033. e-mail: deposit@ccdc.cam.ac.uk) or via internet.





Fig. S1 ORTEP diagram of Compound 4q

Identification code			
Empirical formula	$C_8H_7N_3O_2$		
Formula weight	177.17		
Temperature	298(2) K		
Wavelength	0.71073 Å		
Crystal system	Triclinic		
Space group	P -1		
Unit cell dimensions	a = 5.7205(15) Å	a= 72.891(4)°	
	b = 7.824(2) Å	b= 85.142(4)°	
	c = 9.811(3) Å	$g = 74.695(4)^{\circ}$	
Volume	404.79(19) Å ³		
Z	2		
Density (calculated)	1.454 Mg/m^3		
Absorption coefficient	0.109 mm ⁻¹		
F(000)	184.0		
Crystal size	$0.53 \ge 0.34 \ge 0.13 \text{ mm}^3$		
Theta range for data collection	3.03 to 24.98°.		
Index ranges	-6<=h<=6, -9<=k<=9, -11<=l<=11		
Reflections collected	3825		
Independent reflections	1419 [R(int) = 0.0314]		
Completeness to theta = 24.98°	98.9 %		
Absorption correction	None		
Refinement method	Full-matrix least-squares on F ²		
Data / restraints / parameters	1419 / 0 / 119		
Goodness-of-fit on F^2	1.048		
Final R indices [I>2sigma(I)]	R1 = 0.0567, wR2 = 0.1481		
R indices (all data)	R1 = 0.0745, wR2 = 0.1581		
Largest diff. peak and hole	$0.287 \text{ and } -0.174 \text{ e.\AA}^{-3}$		

Crystallographic description of 3-methyl-5-(pyridin-3-yl)-1,3,4-oxadiazol-2(3H)-one (4q) (Table S1):


¹HNMR and ¹³CNMR Spectra of synthesized compounds

3-methyl-5-phenyl-1,3,4-oxadiazol-2(3*H*)-one (4a):





3-methyl-5-phenyl-1,3,4-oxadiazol-2(3H)-one (4a):


18




5-(4-methoxyphenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4b):











5-(4-bromophenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4d):




5-(3-bromophenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4e):


5-(3-bromophenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4e):




5-(2-bromophenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4f):




5-(2-bromophenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4f):




5-(4-fluorophenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4g):




5-(4-fluorophenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4g):




5-(2-fluorophenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4h):




5-(2-fluorophenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4h):




5-(4-chlorophenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4i):




5-(4-chlorophenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4i):




5-(3-chlorophenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4j):




5-(3-chlorophenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4j):




5-(2-chlorophenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4k):




5-(2-chlorophenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4k):






5-(3,4-dimethoxyphenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4l):





3-methyl-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-2(3H)-one (4m):

5-(3,4-dimethoxyphenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4l):





3-methyl-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-2(3H)-one (4m):






3-methyl-5-(3-nitrophenyl)-1,3,4-oxadiazol-2(3H)-one (4n):






Methyl 4-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl) benzoate(4o):


Methyl 4-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl) benzoate(4o):







3-methyl-5-(naphthalen-2-yl)-1,3,4-oxadiazol-2(3H)-one (4p):

3-methyl-5-(naphthalen-2-yl)-1,3,4-oxadiazol-2(3H)-one (4p):






3-methyl-5-(pyridin-3-yl)-1,3,4-oxadiazol-2(3H)-one (4q):





3-methyl-5-(pyridin-3-yl)-1,3,4-oxadiazol-2(3H)-one (4q):



5-(furan-2-yl)-3-methyl-1,3,4-oxadiazol-2(3*H*)-one (4r):


5-(furan-2-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4r):






5-(1H-indol-2-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4s):


5-(1H-indol-2-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one (4s):







3-methyl-5-(thiophen-2-yl)-1,3,4-oxadiazol-2(3H)-one (4t):


3-methyl-5-(thiophen-2-yl)-1,3,4-oxadiazol-2(3H)-one (4t):







3-benzyl-5-phenyl-1,3,4-oxadiazol-2(3H)-one (5a):









3-benzyl-5-(4-chlorophenyl)-1,3,4-oxadiazol-2(3H)-one (5b):




3-benzyl-5-(4-chlorophenyl)-1,3,4-oxadiazol-2(3H)-one (5b):





3-benzyl-5-(4-fluorophenyl)-1,3,4-oxadiazol-2(3H)-one (5c):







3-benzyl-5-(4-methoxyphenyl)-1,3,4-oxadiazol-2(3H)-one (5d):








3-benzyl-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-2(3H)-one (5f):





3-benzyl-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-2(3H)-one (5f):



3-benzyl-5-(furan-2-yl)-1,3,4-oxadiazol-2(3H)-one (5g):


3-benzyl-5-(furan-2-yl)-1,3,4-oxadiazol-2(3H)-one (5g):






3-benzyl-5-(1H-indol-3-yl)-1,3,4-oxadiazol-2(3H)-one (5h):

3-benzyl-5-(1H-indol-3-yl)-1,3,4-oxadiazol-2(3H)-one (5h):






Methyl 4-(4-benzyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)benzoate (5i):

2-methoxy-5-(3-nitrophenyl)-1,3,4-oxadiazole :

Yield 17 mg, 16%; solid, m.p. 143-145 °C (lit.³ m.p. 147 °C); ¹H NMR (300 MHz, CDCl₃): 8.87 (d, 1H, J = 1.5 Hz), 8.45-8.37 (m, 2H), 7.67 (t, 1H), 4.0 (s, 3H)



References:

1. SADABS V2.10 (Sheldrick, G. M. 2003).

2. (a) Sheldrick, G. M. Acta Crystallogr., Sect. A: Found. Crystallogr., 1990, **46**, 467; (b) Sheldrick, G. M. SHELXL-NT Version 6.12, University of Gottingen, Germany, 2000

3. Shang, Z., Chu, Q., & Tan, S. Synthesis., 2015, 47, 1032-1040.